Lots of possible theories or a combination of them. Perhaps the biotech sector doesn't understand the potential of a device taking the place where drugs are the standard treatment and filling a need where no drugs have been found to work. Perhaps it is a big Biotech/Pharma that wants to keep the price low for a potential future acquisition? Perhaps is is a group a traders that target companies where the share price can easily be manipulated. You don't just make money on increasing share price. You can make money on volatility. If you can easily cause price swings in the 10-20 percent range you have a money making machine. Force the price down to pick up cheap shares, let the price drift back up based the actual merits of the company then take profit. Rinse and repeat. That has been a pattern here for probably about 8 years.
News 
Market Data 
Discover 
